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Abstract: Tiotropium–olodaterol, formulated in the Respimat soft-mist inhaler, is an inhaled 
fixed-dose combination (FDC) of a long-acting muscarinic antagonist (LAMA) and a long-
acting β
2
-agonist (LABA), commercialized under the name of Spiolto or Stiolto. The efficacy 
of tiotropium–olodaterol 5–5 µg once daily in adult patients with COPD was documented in 
eleven large, multicenter trials of up to 52 weeks duration. Tiotropium–olodaterol 5–5 µg not 
only improved spirometric values to a significantly greater extent than placebo but also resulted 
in statistically significant beneficial effects on dyspnea, markers of hyperinflation, use of rescue 
medication, health-related quality of life, and exercise endurance. Improvements exceeded the 
minimal clinically important difference (MCID) for forced expiratory volume in 1 second (FEV
1
), 
dyspnea, and quality of life. Differences between tiotropium–olodaterol 5–5 µg and the respective 
monocomponents were statistically significant for FEV
1
, dyspnea, markers of hyperinflation, use 
of rescue medication, and health-related quality of life, but did not reach the MCID. However, 
dual bronchodilatation significantly increased the number of patients who exceeded the MCID 
for dyspnea and quality of life. Moreover, tiotropium–olodaterol 5–5 µg was significantly more 
effective than salmeterol–fluticasone (FDC) twice daily at improving pulmonary function. Dif-
ferences between tiotropium–olodaterol and other LAMA/LABA FDCs were not observed for 
FEV
1
 or other efficacy markers. Therefore, tiotropium–olodaterol is a valuable option in the 
treatment of COPD patients who remain symptomatic under monotherapy.
Keywords: COPD, bronchodilatation, dyspnea, exacerbation, exercise tolerance, LABA, 
LAMA, spirometry
Introduction
COPD is a preventable and treatable disease characterized by persistent airflow 
limitation caused by smoking and/or exposure to noxious gases. This disease is char-
acterized by chronic and progressive breathlessness, cough, sputum production, and 
reduced exercise tolerance, punctuated by episodes of acute worsening of symptoms 
needing additional treatment and possibly emergency or hospital care. This all even-
tually leads to reduced activities of daily living and poor quality of life. COPD is not 
curable, and represents a major cause of morbidity and mortality with a considerable 
economic and social impact.1
COPD results from persistent pathologic abnormalities in the small airways, 
most often associated with parenchymal destruction, which are both progressive in 
nature and lead to an annual decline in forced expiratory volume in 1 second (FEV
1
) 
that is faster than normal.2–6 Small-airway disease (obstructive bronchiolitis) leads 
to airflow limitation and spirometric abnormalities. Parenchymal destruction and 
loss of alveoli (emphysema) further enhance that airflow limitation and are also 
responsible for an abnormal increase in static lung volumes and a decrease in forced 
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vital capacity (FVC). For many years, the Global Initiative 
for Chronic Obstructive Lung Disease (GOLD) has used 
an FEV
1
:FVC ratio of 0.7 to define airway obstruction in 
COPD patients and classified them into four stages depend-
ing on their postbronchodilator FEV
1
 value. The new GOLD 
COPD classification distinguishes four different patient 
categories, A–D, according to symptoms, degree of airflow 
limitation, and exacerbation history.1 The management of 
COPD consists essentially of smoking cessation, reduction 
of occupational risk factors, influenza vaccination, promotion 
of physical activity, pulmonary rehabilitation, and treatment 
with bronchodilating and anti-inflammatory medicines.1
Scientific and clinical rationale for 
dual long-acting bronchodilatation 
in COPD
In COPD, airway obstruction is partially reversible, being 
regulated by the parasympathetic and sympathetic path-
ways. Although the major part of this reversible component 
is believed to be cholinergic in nature, the activation of 
β
2
-adrenoceptors, which are abundantly present on human 
airway smooth-muscle cells, will stimulate adenyl cyclase 
activity and contribute to smooth-muscle relaxation. Conse-
quently, combining β
2
-agonists and muscarinic antagonists 
is a logical option, not only because a muscarinic antagonist 
can reduce the bronchoconstrictive effect of acetylcholine but 
also because β
2
-agonists reduce the release of acetylcholine, 
and amplify in that way the bronchodilatation elicited by 
direct stimulation of the β
2
-adrenoceptors on the smooth-
muscle cells.7–9
Inhaled short-acting bronchodilators are widely used for 
symptomatic relief in COPD patients at any stage of disease 
severity.1 Their acute effect on FEV
1
 is variable,10 and the 
relationship between spirometric changes and symptoms is 
rather poor.11 Physiological studies have shown, however, 
that better lung emptying, resetting of functional residual 
capacity (FRC) at a lower lung volume, and hence a reduc-
tion in lung hyperinflation are the main mechanisms by 
which COPD patients derive symptomatic benefits from 
inhaled short-acting bronchodilators.12–14 Although maximal 
bronchodilatation can be achieved with a high dose of one 
single agent, combining two different classes of short-acting 
bronchodilators allows the use of lower doses, with the same 
efficacy results and fewer adverse effects.15
Tiotropium (TIO) was the first 24-hour long-acting 
muscarinic antagonist (LAMA) specifically developed for 
the treatment of COPD. It not only improves spirometric 
variables, dyspnea, and exercise tolerance13,16 but also results 
in significant enhancements in quality of life, improved 
responses to pulmonary rehabilitation, and significant 
reductions in exacerbation rate.17,18 Likewise, long-acting 
β
2
-agonists (LABAs) yield beneficial effects on dyspnea, 
exercise tolerance, and quality of life to an extent that 
is largely comparable in magnitude with those of TIO.19 
However, TIO provides better protection against exacerba-
tions compared to LABAs, such as salmeterol (SALM) and 
indacaterol (IND).19–21 The GOLD strategy currently recom-
mends the addition of a second long-acting bronchodilator for 
patients in GOLD COPD classes B–D to optimize symptom 
relief and produce greater and more sustained bronchodilata-
tion in cases where the patient’s symptoms have not improved 
with single agents.1
In the last few years, the number of LABAs and LAMAs 
has expanded, adding several agents to the first-generation 
long-acting bronchodilators: SALM and formoterol (FORM) 
as LABAs and TIO as a LAMA. These include IND, olodat-
erol (OLO), and vilanterol (VIL) as LABAs, and glycopyrro-
nium (GLY), aclidinium (ACL), and umeclidinium (UMEC) 
as LAMAs.7,8 In the light of the GOLD recommendations, 
pharmaceutical companies have combined LAMAs and 
LABAs in one inhaler.
Four LAMA/LABA fixed-dose combinations (FDCs) are 
currently approved by the European Medicines Agency for the 
treatment of COPD: UMEC/VIL, TIO/OLO, and GLY/IND 
as once-daily FDCs, and ACL/FORM as a twice-daily 
FDC. Conversely, the US Food and Drug Administration 
has approved only UMEC/VIL and TIO/OLO as once-daily 
FDCs and ACL/FORM and GLY/IND as twice-daily FDCs, 
the latter at a reduced dose.22 A fifth FDC, GLY/FORM, is 
still under clinical development.
The purpose of this review is to assess the clinical effects 
of TIO/OLO FDCs at the recommended daily dose of TIO 
5 µg and OLO 5 µg (TIO/OLO 5/5 µg, ie, two inhalations 
of TIO/OLO 2.5/2.5 µg once daily). The first part of this 
review focuses on differences between TIO/OLO 5/5 µg 
and placebo, between TIO/OLO 5/5 µg and their respective 
monocomponents TIO and OLO, and between TIO/OLO 
5/5 µg and the LABA–inhaled corticosteroid (ICS) FDC 
SALM–fluticasone (FLU). The second part concentrates on 
comparisons between TIO/OLO 5/5 µg and other LAMA/
LABA FDCs, whereas the potential clinical benefits of adding 
a LABA to a LAMA in the treatment of COPD are reviewed 
in the last part of the paper. The pharmacological properties 
of TIO/OLO 5/5 µg FDC will not be considered in this paper, 
as they have recently been reviewed in detail elsewhere.23–25 
Safety issues are however briefly summarized.
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Therapeutic efficacy
Data presented in this section are based on several Phase III, 
multicenter, randomized, double-blind, controlled studies 
on the effects of TIO/OLO 5/5 µg in patients with COPD 
(Table 1). In these studies, over 10,000 patients have been 
involved. Ten of these studies (eight of which were replicate 
studies) have been published as full papers in peer reviewed 
journals,26–31 one being available only as a European Respi-
ratory Society abstract.32 Four studies used a crossover 
design,26,29,31,32 six studies were placebo controlled,26,28,31,32 and 
four studies compared TIO/OLO with TIO and/or OLO as 
monotherapy.27,30 In one trial, TIO/OLO was compared with 
the LABA/ICS SALM/FLU FDC.29 Based on findings from 
earlier dose-ranging studies,33 two once-daily dosages of TIO/
OLO, 2.5/5 and 5/5 µg were assessed in these trials. This sec-
tion focuses only on the data of the currently recommended 
dosage of once-daily TIO/OLO 5/5 µg, which generally 
provides greater benefits than the once-daily 2.5/5 µg dos-
age in terms of pulmonary function, health-related quality of 
life (HR-QoL) and most other COPD outcomes. In almost 
all studies, TIO/OLO FDC was formulated in the Respimat® 
soft-mist inhaler. In the first two replicate studies,30 however, 
TIO and OLO were inhaled separately via HandiHaler® and 
Respimat, respectively. In these two studies, TIO was pro-
vided at the equivalent dose of 18 µg per inhalation.
In all these randomized controlled trials (RCTs), 
patients were aged 40 years and were current or former 
cigarette smokers, with a smoking history of 10 pack-
years. Importantly, patients with a current diagnosis of 
asthma or other known respiratory disorders were excluded. 
Patients participating in these studies exhibited postbron-
chodilator FEV
1
:FVC ratio 0.7 and postbronchodilator 
FEV
1
 80%26,27 or 30%–80% of the predicted value.28–32 
An overview of the key characteristics of the TIO/OLO 
Table 1 Completed Phase III studies comparing clinical effects of tiotropium–olodaterol fixed-dose combinations with mono-
components and/or placebo in patients with COPD
Title Study Daily treatments  
(patients randomized)
Primary end point Key secondary end points
ANHeLTO 1+2 Zuwallack et al30 OLO 5 µg + TIO 18 µg (567/566)a
TIO 18 µg (565/566)
Fev1 AUC0–3 at week 12
Trough FEV1 at week 12
SGRQ total score at week 12
TONADO 1+2 Buhl et al27 TIO/OLO 5/5 µg (522/507)
TIO/OLO 2.5/5 µg (522/508)
OLO 5 µg (528/510)
TIO 5 µg (527/506)
TIO 2.5 (525/507)
Fev1 AUC0–3 at week 24
Trough FEV1 at week 24
SGRQ at week 24
TDI at week 24
vIvACITO Beeh et al26 TIO/OLO 5/5 µg (139)
TIO/OLO 2.5/5 µg (136)
OLO 5 µg (138)
TIO 5 µg (138)
TIO 2.5 (137)
PLA (138)
Fev1 AUC0–24 at week 6 Fev1 AUC0–12 at week 6
Fev1 AUC12–24 at week 6
Peak Fev1 AUC0–3 at week 6
Trough FEV1 at week 6
ΔRv and ΔFRC at week 6
OTeMTO 1+2 Singh et al28 TIO/OLO 5/5 µg (204/202)
TIO/OLO 2.5/5 µg (202/202)
TIO 5 µg (204/203)
PLA (204/202)
SGRQ at week 12
Fev1 AUC0–3 at week 12
Trough FEV1 at week 12
TDI at week 12
eNeRGITO Beeh et al29 TIO/OLO 5/5 µg (221)
TIO/OLO 2.5/5 µg (215)
SALM/FLU 50/500 µg BID (215)
SALM/FLU 50/250 µg BID (212)
Fev1 AUC0–12 at week 6 Fev1 AUC0–24
Fev1 AUC12–24 at week 6
Peak Fev1 AUC0–3 at week 6
Trough FEV1 at week 6
TORRACTO Maltais et al32,b TIO/OLO 5/5 µg (139)
TIO/OLO 2.5/5 µg (133)
PLA (132)
Endurance time during constant work 
rate cycle ergometry at week 12
Endurance time during shuttle 
walking test at week 12
Pre-exercise IC at week 12
MORACTO 1+2 O’Donnell et al31 TIO/OLO 5/5 µg (226/224)
TIO/OLO 2.5/5 µg (223/219)
TIO 5 µg (227/218)
OLO 5 µg (217/219)
PLA (222/216)
Pre-exercise IC at week 6
Endurance time during constant 
work-rate cycle ergometry at week 6
Notes: aTreatments were inhaled separately via OLO Respimat and TIO HandiHaler; bavailable only as abstract. 1+2, replicate studies.
Abbreviations: AUC, area under the curve; BID, bis in die (twice daily); FEV1, forced expiratory volume in 1 second; IC, inspiratory capacity; PLA, placebo; SALM/FLU, 
salmeterol/fluticasone; SGRQ, St George’s Respiratory Questionnaire (score); TDI, Transition Dyspnea Index; TIO/OLO, tiotropium–olodaterol fixed-dose combination; 
ΔRV, change in RV after treatment versus placebo; ΔFRC, change in FRC after treatment versus placebo.
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RCTs is provided in Table 1. The majority of patients in 
the ANHELTO, VIVACITO, OTEMTO, TONADO, and 
ENERGITO studies belonged to GOLD stage II (50%–72%) 
or stage III (27%–40%).26–30 COPD stage IV patients were 
absent in the ENERGITO, MORACTO, and TORRACTO 
studies,29,31,32 whereas for the ANHELTO, OTEMTO, 
VIVACITO, and TONADO studies only 0.2%, 0.5%–1.5%, 
2%, and 10%–12%, respectively, were classified as GOLD 
stage IV.26–28,30 The distribution of COPD patients according 
to the new GOLD subgroups was available for two studies: 
in OTEMTO, 30% of the patients belonged to GOLD sub-
group A, 30% to subgroup B, 15.3% to subgroup C, and 
24.7% to subgroup D, whereas in TONADO 41.3% were 
classified as GOLD subgroups A and B and 58.7% as GOLD 
subgroups C and D.34,35
The percentage of patients on ICS varied between 
9.6% for ENERGITO and 34.8%–41.9% for OTEMTO, 
35.8%–37.8% for ANHELTO, 41.1% for VIVACITO, and 
45.1%–49.2% for TONADO.26,28–30 Between 0.2% and 11% 
of patients were on xanthines.26,27,29,36 Inhaled salbutamol 
was provided as rescue medication for use throughout these 
studies.
Comparison between TIO/OLO 5/5 µg 
and placebo
FDC TIO/OLO 5/5 µg was associated with clinically and 
statistically significant benefits over placebo for several 
measures of efficacy and HR-QoL (Tables 2 and 3).
Pulmonary function
TIO/OLO 5/5 µg once daily was effective in improving 
pulmonary function in patients with COPD in one 6-week 
and two 12-week trials.26,28 Compared with placebo, dual 
bronchodilatation significantly improved the 0- to 24-hour 
weighted mean FEV
1
 by 280 mL and trough FEV
1
 by 160 mL, 
as well as the FEV
1
 area under the curve (AUC) from 0 
to 12 hours (FEV
1
 AUC
0–12
), FEV AUC
12–24
, and FEV
1
 AUC
0–3
 
after 6 weeks.26 Similar observations were made for trough 
FEV
1
 (160 mL) and FEV
1
 AUC
0–3
 after 12 weeks of treatment 
in another study.28 All improvements exceeded the threshold 
of clinical significance, estimated to be 100–140 mL.37,38
Symptoms
TIO/OLO 5/5 µg once daily was associated with statistically 
and clinically significant benefits in dyspnea relative to pla-
cebo. In OTEMTO 1 and 2, TIO/OLO 5/5 µg significantly 
improved Mahler Transition Dyspnea Index (TDI) focal 
scores at 12 weeks compared with placebo by 2.05 and 
1.2 units, respectively,28 exceeding the minimal clinically 
important difference (MCID) of 1 unit defined for that 
variable.37,38 The overall number of responders was 53.9% 
after TIO/OLO 5/5 µg and 26.2% after placebo. Consistent 
with these findings, significantly more patients on TIO/OLO 
5/5 µg than placebo recipients also reduced the use of rescue 
medication from three puffs/day to 1.8 puffs/day.39
Health-related quality of life
Clinically and statistically significant differences were 
observed between once-daily TIO/OLO 5/5 µg and placebo 
for HR-QoL. St George’s Respiratory Questionnaire (SGRQ) 
scores decreased by 4.89 units and 4.56 units compared with 
placebo in OTEMTO 1 and 2, respectively.28 The percent-
age of patients classified as SGRQ responders (defined 
as an improvement from baseline exceeding 4 units)37,38 
Table 2 Differences in TIO/OLO 5/5 µg, TIO monotherapy, OLO monotherapy, and PLA for different spirometric end points derived 
from key clinical studies
Study AUC0–24 FEV1 (mL) Peak0–3 FEV1 (mL) AUC0–3 FEV1 (mL) Trough FEV1 (mL)
TIO/OLO 5/5 µg vs PLA
Beeh et al26 Δ=280 411 vs 72 201 vs -6
Singh et al28 Δ=331 and Δ=299 Δ=162 and Δ=166
TIO/OLO 5/5 µg vs TIO 5 µg
Beeh et al26 Δ=110 411 vs 300 201 vs 122
Singh et al28 Δ=111 and Δ=105 Δ=28 and Δ=39
Buhl et al27 Δ=117 and Δ=103 Δ=71 and Δ=50
TIO 18 µg + OLO 5 µga vs TIO 18 µg
Zuwallack et al30 Δ=117 and Δ=106 Δ=60 and Δ=40
TIO/OLO 5/5 µg vs OLO 5 µg
Beeh et al26 Δ=115 411 vs 291 201 vs 109
Buhl et al27 Δ=123 and Δ=132 Δ=82 and Δ=88
Note: aTreatments inhaled separately via OLO Respimat and TIO HandiHaler.
Abbreviations: AUC, area under the curve; FEV1, forced expiratory volume in 1 second; PLA, placebo; TIO/OLO, tiotropium–olodaterol fixed-dose combination.
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at 12 weeks increased from 31.9% in the placebo arm to 
52.4% (full analysis) with TIO/OLO 5/5 µg (Table 2), with 
an odds ratio of being a responder for TIO/OLO 5/5 µg versus 
placebo of approximately 2.5 (95% confidence interval 
[CI] 1.6–3.8).28
Markers of hyperinflation and exercise tolerance
TIO/OLO 5/5 µg was associated with reductions in FRC and 
residual volume (RV) at 2 hours 30 minutes and 22 hours 
30 minutes postdose relative to placebo (Figure 1). Changes 
from baseline for FRC were -547 mL after TIO/OLO 5/5 
and -52 mL after placebo at 2.5 hours postdose. Even at 
22.5 hours postdose, the difference between TIO/OLO 5/5 µg 
and placebo exceeded 300 mL. These improvements in FRC 
and RV were mirrored by changes in inspiratory capacity 
(IC): 351 mL after TIO/OLO 5/5 µg and 16 mL after placebo 
compared with baseline values 2.5 hours postdose.26 Differ-
ences between treatments still averaged 200 mL 22.5 hours 
postdose and reached statistical significance. These beneficial 
effects of TIO/OLO 5/5 µg on hyperinflation at rest were 
confirmed in three other placebo-controlled crossover studies. 
The MORACTO studies demonstrated that TIO/OLO 5/5 µg 
once daily improved IC by 244 and 265 mL after 6 weeks, 
whereas TORRACTO showed an IC increase of 234 mL 
Table 3 Differences in TIO/OLO 5/5 µg, TIO monotherapy, OLO monotherapy, and PLA in key clinical studies, highlighting number 
of responders and number needed to treat
Study TDI TDI responders (%) NNT (95% CI) SGRQ SGRQ responders (%) NNT (95% CI)
TIO/OLO 5/5 µg vs PLA
Singh et al28 2.1 and 1.2 53.9 vs 26.2 4 (3.1–4.2) -4.89 and -4.59 53.1 vs 31.2 and
51.8 vs 32.6
5 (3.8–5.7) and
6 (4.2–6.6)
TIO/OLO 5/5 µg vs TIO 5 µg
Singh et al28 0.6 and 0.6 53.9 vs 41 8 (5.8–11.7) -2.49 and -1.72 53.1 vs 41.7 and
51.8 vs 41.1
9 (6.3–14.2) and
10 (6.6–15.7)
Buhl et al27 0.4 54.9 vs 50.6 (NS) 24 (NS) -1.23 57.5 vs 48.7 12 (7.6–22.5)
TIO 18 µg + OLO 5 µg vs TIO 18 µg
Zuwallack et al30 -1.85 49.3 vs 42.5 15 (9–40)
TIO/OLO 5/5 µg vs OLO 5 µg
Buhl et al27 0.4 54.9 vs 48.2 15 (9–42.9) -1.69 57.5 vs 44.8 8 (5.9–12)
Abbreviations: NNT, number needed to treat; CI, confidence interval; NS, not significant; PLA, placebo; SGRQ, St George’s Respiratory Questionnaire (score); 
TDI, Transition Dyspnea Index; TIO/OLO, tiotropium–olodaterol fixed-dose combination.
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after a 12-week treatment with TIO/OLO 5/5 µg.23,40,41 These 
gains in IC persisted during exercise and contributed to 
significantly improved exercise endurance upon treatment 
with TIO/OLO 5/5 µg. Compared with placebo, endurance 
time during constant work-rate cycle ergometry increased 
by 79 and 54 seconds in MORACTO31 and 64 seconds 
in TORRACTO.32 Breathing discomfort at isotime was 
reduced in patients treated with TIO/OLO 5/5 µg, with mean 
Borg scale values of 4.44 with TIO/OLO 5/5 µg and 5.14 
with placebo.31 In that study, the endurance shuttle-walk 
test also increased by 21% with TIO/OLO 5/5 µg at week 
12 compared with placebo.
Comparison between TIO/OLO 5/5 µg 
and TIO 5 µg monotherapy
For a variety of clinical endpoints, differences between 
TIO/OLO 5/5 µg FDC and TIO 5 µg monotherapy – both 
administered via the Respimat soft-mist inhaler – generally 
reached statistical significance in favor of dual bronchodi-
latation, without however reaching the threshold of clinical 
significance (Tables 2 and 3). However, we need to take into 
account the fact that thresholds of MCIDs have been estab-
lished in the past by comparing a single active treatment with 
placebo. Whether the same thresholds of MCIDs should be 
applied when comparing dual combinations with their active 
monocomponents is still a matter of debate.38
Pulmonary function
Data from the VIVACITO trial showed that once-daily TIO/
OLO 5/5 µg produced significant improvements in FEV
1
 
AUC
0–24
, FEV
1
 AUC
0–12
, and FEV
1
 AUC
12–24
 compared with 
once-daily TIO 5 µg monotherapy (Table 2).26 Moreover, 
TIO/OLO 5/5 µg also significantly improved AUC
0–3
 FEV
1
 
and trough FEV
1
 at the end of the study period compared 
with TIO 5 µg. Likewise, ANHELTO 1 and 2 showed that 
dual bronchodilatation also improved pulmonary function 
significantly more than once-daily monotherapy with TIO.30 
In these two replicate studies, OLO 5 µg was inhaled via 
the Respimat, while TIO 18 µg (equivalent to TIO 5 µg 
via Respimat) was administered via HandiHaler. In the 
OTEMTO 1 and 2 studies, statistically significant differ-
ences in favor of TIO/OLO 5 µg were seen at the end of the 
study periods compared with TIO 5 µg monotherapy. Dif-
ferences ranged between 105 and 111 mL for peak AUC
0–3
 
FEV
1
 and between 28 and 39 mL for trough FEV
1
.28 Similar 
findings were observed in TONADO, in which more than 
5,000 patients were involved:27 statistically significant 
improvements were noted for both AUC
0–3
 FEV
1
 and trough 
FEV
1
 with TIO/OLO 5 µg compared with TIO 5 µg after 
24 weeks (Table 2). These improvements in FEV
1
 persisted 
for 52 weeks. Responses in trough FVC and AUC
0–3
 FVC 
to once-daily TIO/OLO 5/5 µg and TIO 5 µg were similar 
to those reported in other trials.28
Symptoms and use of rescue medication
As summarized in Table 3, TIO/OLO 5/5 µg differed signifi-
cantly from TIO 5 µg monotherapy in terms of alleviating 
symptoms of dyspnea, as measured by TDI at week 12, the 
mean difference equaling approximately 0.6 units in both 
OTEMTO studies.28 The overall number of responders on 
the TDI was 53.9% after TIO/OLO 5 µg and 41% after TIO 
5 µg, corresponding with a number needed to treat (NNT) of 
eight.39 TIO/OLO 5/5 µg also significantly lowered the use 
of rescue salbutamol more than TIO 5 µg: 1.8 puffs/day for 
dual bronchodilatation versus 2.4 puffs/day for once-daily 
TIO 5 µg.39 TONADO showed comparable statistically sig-
nificant differences between TIO/OLO 5/5 µg and TIO 5 µg, 
with a difference in TDI of 0.36 units in favor of double bron-
chodilatation. In this study, daytime use of rescue salbutamol 
was 0.97 puffs/day with TIO 5 µg and 0.76 puffs/day with 
TIO/OLO 5/5 µg, whereas the nighttime use of salbutamol 
was 1.69 and 1.24 puffs/day, respectively.27,40,41 ANHELTO 
had already previously demonstrated that the number of 
rescue-medication-free days increased by about 8% with the 
combination treatment compared with TIO monotherapy.30
Health-related quality of life
OTEMTO 1 and 2 demonstrated that overall improvements in 
SGRQ with TIO 5 µg were small compared to placebo (-2.4 
[P0.05] and -2.85 units [not significant]) and did not reach 
the MCID.28 This contrasts with improvements of more than 
4 units with TIO/OLO 5/5 µg compared with placebo. The 
likelihood of becoming a responder for the SGRQ compared 
with baseline was 41.4% with TIO 5 µg and 52.4% with 
TIO/OLO 5/5 µg, with an odds ratio of approximately 1.5, 
corresponding with an NNT of nine to ten (Table 3). Similar 
observations were made in ANHELTO (Table 3).30 More 
pronounced clinically meaningful improvements in SGRQ 
total scores were reached in TONADO with TIO/OLO 
5/5 µg (-6.8 units) and TIO 5 µg (-5.6 units) compared to 
baseline.27 The difference between TIO/OLO 5/5 µg and TIO 
5 µg (1.2 units) reached statistical significance but failed to 
reach the threshold of MCID. In that study, the number of 
participants exhibiting an MCID in HR-QoL increased com-
pared with baseline from 48.7% with TIO 5 µg to 57.5% with 
TIO/OLO 5/5, corresponding to an NNT of 12.
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Markers of hyperinflation and exercise tolerance
Reductions in FRC and RV measured 2.5 and 22.5 hours 
after inhalation of TIO 5 µg were smaller (431 mL) than 
those obtained with TIO/OLO 5/5 µg (547 mL). This dif-
ference corresponded to a 100 mL difference in increase in 
IC between TIO/OLO 5/5 µg and TIO 5 µg.26 Similar differ-
ences (114 and 88 mL) in improvement in IC were observed 
between TIO/OLO 5/5 and TIO 5 in two other 6-week 
studies, and these differences persisted during exercise.31 
In the exercise studies, no differences were observed for 
endurance time or Borg score for dyspnea during constant 
work-rate cycle ergometry after 6 weeks between TIO 5 µg 
and TIO/OLO 5/5. However, in a subgroup of severely 
hyperinflated COPD patients, statistically significant dif-
ferences in endurance time during constant work rate were 
observed between TIO 5 µg and TIO/OLO 5/5 µg in favor 
of dual bronchodilatation.31
exacerbations
Only correctly powered studies enrolling large number of 
COPD patients at high risk of exacerbations (based upon 
prior exacerbation history and severity of airflow obstruc-
tion) will elucidate the question of whether dual broncho-
dilatation is superior to TIO monotherapy for prevention of 
exacerbations. Such a study, DYNAGITO, comparing the 
effects of TIO/OLO 5/5 µg and TIO 5 µg and investigating 
as primary outcome the annualized rate of moderate-to-
severe COPD exacerbations over 1 year, is ongoing and 
registered as NCT02296138 at ClinicalTrials.gov. Although 
the TONADO studies were not designed to assess this impor-
tant issue, their 52-week duration was sufficient to explore 
the potential effects of the interventions on the occurrence 
of exacerbations.27 In TONADO, a moderate exacerbation 
was defined by the need for systemic steroids or antibiotics, 
whereas a severe exacerbation required hospitalization. In the 
combined data set, the percentage of patients with at least 
one moderate-to-severe COPD exacerbation was 27.7% for 
the TIO/OLO 5/5 µg FDC and 28.8% with TIO 5 µg. Unex-
pectedly, the percentage of patients with at least one severe 
COPD exacerbation was 5.9% (n=61) for TIO/OLO 5/5 µg 
and 4.5% (n=47) for TIO 5 µg. These differences did not 
reach statistical significance.27,42
Comparison between TIO/OLO 5/5 µg 
and OLO 5 µg monotherapy
As in the comparison between once-daily TIO/OLO 5/5 µg 
FDC and once-daily TIO 5 µg, differences between TIO/OLO 
5/5 µg FDC once-daily and OLO 5 µg once-daily, both 
administered via the Respimat soft-mist inhaler, were gener-
ally statistically but not clinically significant in favor of dual 
bronchodilatation (Tables 2 and 3).
Pulmonary function
FEV
1
 AUC
0–24
, FEV
1
 AUC
0–12
, FEV
1
 AUC
12–24
, FEV
1
 AUC
0–3
, 
and trough FEV
1
 increased significantly after a 6-week treat-
ment with once-daily TIO/OLO 5/5 µg compared with once-
daily OLO 5 µg monotherapy in VIVACITO26 (Table 1). 
Similar findings were observed in TONADO, which demon-
strated statistically significant improvements in FEV
1
 AUC
0–3
 
and trough FEV
1
 for TIO/OLO 5 µg in comparison with OLO 
5 µg, persisting for 52 weeks. Similar responses in trough 
FVC and FVC AUC
0–3
 were also observed in that study.27
Symptoms and use of rescue medication
Statistically significant differences between TIO/OLO 
5/5 µg and OLO 5 µg were observed in TONADO, reaching 
0.42 units for the TDI in favor of double bronchodilatation 
(P0.005). Moreover, daytime use of rescue salbutamol 
was 0.87 puffs/day with OLO 5 µg and 0.76 puffs/day with 
TIO/OLO 5/5 µg, whereas nighttime use of salbutamol was 
1.52 and 1.24 puffs/day, respectively.27,40,41
Health-related quality of life
In TONADO, changes in SGRQ total scores compared 
with baseline with OLO 5 µg reached -5.1 units (compared 
with -6.8 units after double bronchodilatation). The dif-
ference between TIO/OLO 5/5 µg and OLO 5 µg was thus 
1.7 units, which did not reach the threshold of minimal 
clinical significance.27 In that study, the number of responders 
on the SGRQ compared with baseline increased from 44.8% 
with OLO 5 µg to 57.5% with TIO/OLO 5/5 µg, correspond-
ing to an NNT of eight.27
Markers of hyperinflation and exercise tolerance
Reductions in FRC and RV versus baseline measured 
2.5 hours after inhalation of OLO 5 µg were smaller 
(435 mL) than those with TIO/OLO 5/5 µg (547 mL). 
Reciprocal increases in IC were 242 mL with OLO 5 µg 
and 351 mL with TIO/OLO 5/5 µg 2.5 hours after inha-
lation.26 Differences in IC between TIO/OLO 5/5 µg and 
OLO 5 µg were similar in magnitude in two other 6-week 
studies (119 and 80 mL) and these differences persisted 
during exercise.31,40,41 Endurance time during constant work-
rate cycle ergometry after TIO/OLO 5/5 µg increased by 
47 seconds in MORACTO 2, whereas no such increase was 
seen in MORACTO 1.31
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exacerbations
In the combined data set of TONADO, the percentage of 
patients with at least one moderate-to-severe COPD exacer-
bation was 27.7% for the TIO/OLO 5/5 µg FDC and 31.9% 
with OLO 5 µg. As assessed by Kaplan–Meier estimates, the 
risk of a moderate-to-severe exacerbation was significantly 
lower with TIO/OLO 5/5 µg than with OLO 5 µg, with a risk 
ratio of 0.83 (95% CI 0.71–0.99). Indices for severe exacerba-
tions were comparable between TIO/OLO 5/5 µg FDC and 
OLO 5 µg, since the percentage of patients with at least one 
severe COPD exacerbation was 5.9% (n=61) for TIO/OLO 
5/5 µg and 5.4% (n=56) for OLO 5 µg.27,42
Comparison between TIO/OLO 5/5 µg 
and salmeterol–fluticasone propionate
In a 6-week trial that enrolled more than 200 patients 
with COPD, the effects of dual bronchodilatation and two 
strengths of SALM/FLU twice daily were compared with 
regard to the FEV
1
 AUC
0–12
 (primary end point), FEV
1
 
AUC
12–24
, FEV
1
 AUC
0–24
, FEV
1
 peak
0–3
, and trough FEV
1
. 
Treatment with TIO/OLO 5/5 µg once daily produced 
significantly greater improvements in pulmonary function 
than SALM/FLU 50/500 µg and 50/250 µg twice daily 
after 6 weeks.29 Greater improvements in FEV
1
 AUC
0–12
 of 
approximately 125 mL were observed with TIO/OLO 5/5 µg 
compared with either dose of SALM/FLU. Treatment with 
TIO/OLO 5/5 µg once daily improved FEV
1
 values with 
approximately 85 mL over the full 24-hour dosing interval 
compared with SALM/FLU.
Efficacy according to the COPD 
subgroups
A post hoc analysis of TONADO shows that the broncho-
dilating properties of TIO/OLO 5/5 µg remained preserved 
in more severe stages of COPD.43 Post hoc analyses have 
also been performed for both OTEMTO and TONADO in 
an attempt to differentiate effects of treatments between the 
GOLD COPD subgroups A–D. It should however be pointed 
out that these studies were designed and initiated before the 
2011 GOLD update.1 In OTEMTO, TIO/OLO was more 
effective than placebo at improving FEV
1
 AUC 
0–3
, trough 
FEV
1
, SGRQ total score, and TDI focal score in all GOLD 
A–D subgroups. When comparing TIO/OLO 5/5 µg to TIO 
5 µg monotherapy, FEV
1
 AUC
0–3
, trough FEV
1
, and TDI 
improved in all GOLD A–D subgroups. For FEV
1
 AUC
0–3,
 
the level of significance was reached for all subgroups, 
whereas statistical significance was reached only for trough 
FEV
1
 in the A, B, and D subgroups and for TDI only in the 
C subgroup. Likewise, treatment effects differed between 
subgroups for SGRQ total score, improvements being most 
evident in the GOLD B subgroup.35 In TONADO, numeri-
cally greater responses in both FEV
1
 AUC
0–3
 and trough 
FEV
1
 were demonstrated in patients classified as GOLD A/B 
compared to patients classified as GOLD C/D, with statisti-
cally significant differences between TIO/OLO 5/5 µg and 
both monotherapies in each subgroup.34
Safety issues
Overall, the TIO/OLO FDC appears to be well tolerated and 
devoid of important side effects. In OTEMTO, the incidence 
of adverse events (AEs) was higher in the placebo than in 
the actively treated groups, leading to more frequent discon-
tinuation of the study in the placebo group.28 In VIVACITO, 
however, AEs were balanced among the different treatment 
groups.26 In the combined analysis of the 52-week TONADO, 
the overall incidence of AEs was 74%, 73.3%, and 76.6% for 
TIO/OLO, TIO, and OLO, respectively. Most of these were 
of mild or moderate severity, without differences between 
treatments. Treatment-related AEs were reported in 7.1%, 
6.1%, and 6.6% of patients on TIO/OLO, TIO, and OLO, and 
serious AEs (SAEs) in 16.4%, 16.7%, and 17.4% of patients, 
respectively. The most common SAEs in TIO/OLO, TIO, and 
OLO recipients were of respiratory origin: COPD exacerba-
tions (6.9%, 6.3%, and 6.5%, respectively) and pneumonias 
(1.7%, 0.9%, and 1.4%, respectively).27 Withdrawals from 
the study because of AEs were noted in 7.4%, 9%, and 9.9% 
of patients, respectively.27 The incidence of cardiovascular 
SAEs was 1.8%, 1.8%, and 1.4% and that of cerebrovascular 
SAEs 0.5%, 0.5%, and 0.6% in the respective groups, without 
significant differences between the treatment groups.27 More 
detailed reports on tolerability and AEs of TIO/OLO can be 
found elsewhere.22–25,44,45
Comparisons between tiotropium/
olodaterol 5/5 µg fixed-dose 
combination and other LAMA/
LABA fixed-dose combinations
Since none of the currently licensed LAMA/LABA FDCs 
have been compared in head-to-head RCTs, they can only 
be weighed against each other by indirect comparisons. Such 
comparisons are difficult to perform, and their conclusions 
should be interpreted with great caution. Indeed, important 
between-study differences exist on how classical outcomes, 
such as reversibility of airway obstruction, QoL, exercise 
tolerance, dyspnea, and rate of exacerbations, are assessed 
and expressed. Moreover, study design, distribution of COPD 
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severity within the study population, exacerbation history, 
symptoms, concomitant ICS use, age and sex, degree of 
hyperinflation, and reversibility, as well as baseline exercise 
capacity and knowledge of inhaler technique, may affect the 
outcome of a pharmacological intervention with bronchodila-
tors to a certain extent. Likewise, seasonal effects and (even 
more) the Hawthorne effect (ie, beneficial effects observed 
in RCTs due to the fact that patients who are participating in 
an RCT change their behavior, such as improved adherence 
to maintenance treatment and better inhaler technique) may 
further complicate comparisons between studies.
In order to weigh the existing LABA/LAMA formula-
tions among one other, data from placebo-controlled studies 
may be completed with a “network meta-analysis”, which 
allows the combination of trials involving different sets of 
treatments, to end up with an integrated and structured single 
analysis. Data are now available comparing the effects of four 
LABA/LAMA FDCs for such end points as trough FEV
1
, 
TDI, and QoL, using that specific technique.
Placebo-controlled studies
Despite some limitations, placebo-controlled trials allow 
comparison to a certain extent of the magnitude of clinical 
effects of other LAMA/LABA FDCs and TIO/OLO 5/5 µg 
with a common comparator – placebo. However, placebo-
controlled trials with LAMA/LABA FDCs other than 
TIO/OLO are limited in number (Table 4). Overall, it appears 
that the magnitude of the effect observed with currently 
marketed FDCs is strikingly similar to those seen with TIO/
OLO for trough FEV
1
, TDI, and HR-QoL (Table 2).46–49 
Likewise, the reported differences between GLY/IND 
50/110 µg and placebo for lung volumes (-520 mL for 
FRC and 340 mL for IC at 1 hour postdose) are strikingly 
similar to the changes seen 2.5 hours postdose with TIO/
OLO 5/5 µg.50 In two replicate studies assessing the effects 
of UMEC/VIL 62.5/25 µg on lung volumes, differences 
from placebo were -238 and -351 mL for trough FRC, -295 
and -466 mL for trough RV, and 238 and 316 mL for IC 
3 hours postdose.51
Trough FEV1
In a recently published network meta-analysis,22 Calzetta 
et al used clinical data from more than 23,000 patients 
to compare the effects of four LABA/LAMA FDCs with 
monocomponents. They demonstrated that TIO/OLO 5/5 µg 
increased trough FEV
1
 by 55 mL (95% CI 46–64) compared 
to monocomponents, whereas UMEC/VIL 62.5/25 µg, ACL/
FORM 400/12 µg, and GLY/IND 50/110 µg increased trough 
FEV
1
 by 84 mL (95% CI 66–102), 46 mL (95% CI 18–74), 
and 89 mL (95% CI 76–103) compared to monotherapy, 
respectively. For GLY/IND, efficacy did not depend on 
the regimen of administration (once daily, 92 mL [95% CI 
73–110]; twice daily, 91 mL [95% CI: 66–115]). Surpris-
ingly, the lower dose of UMEC/VIL 62.5/25 µg elicited a 
greater increase in trough FEV
1
 when compared with UMEC/
VIL 125/25 µg (95 mL [95% CI 73–117] versus 72 mL [95% 
CI 44–100], respectively), although the difference was not 
statistically significant. For none of the FDCs did differences 
between dual bronchodilatation and monocomponents exceed 
the generally accepted MCID for FEV
1
 of 100 mL.37,38 The 
network meta-analysis presented by Calzetta et al suggested 
that a gradient of effectiveness among the different drug 
combinations may exist, with UMEC/VIL slightly exceed-
ing the effects of GLY/IND (-12 mL), TIO/OLO (-30 mL), 
and ACL/FORM (-49 mL), though statistically significant 
differences among the FDCs were not observed.22 Moreover, 
Table 4 Differences between several LAMA/LABA fixed-dose combinations and PLA
Study n Trough FEV1 (mL) SGRQ TDI FRC/IC (mL) ET (s)
GLY/IND 110/50 µg vs PLA
Bateman et al46 2,144 Δ=200 Δ=-3 Δ=1.1
Beeh et al50 84 Δ=-520/Δ=340 Δ=60
UMEC/VIL 62.5/25 µg vs PLA
Donohue et al47 1,536 Δ=167 Δ=-5.5 Δ=1.2
Maltais et al51 308 -/Δ≈250 Δ=69.4
Maltais et al51 349 -/Δ≈400 Δ=21.9
ACL/FORM 400/12 µg BID vs PLA
D’Urzo et al48 1,692 -35 vs 94 -6.57 vs -2.21 2 vs 0.6
Singh et al49 1,729 Δ=143 -8.3 vs -6.5 2.5 vs 1.2
Abbreviations: ACL/FORM, aclidinium–formoterol fixed-dose combination; BID, bis in die (twice daily); ET, endurance time (during constant work-rate cycle ergometry); 
Fev1, forced expiratory volume in 1 second; FRC, functional residual capacity; GLY/IND, glycopyrronium–indacaterol fixed-dose combination; IC, inspiratory capacity; 
LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; PLA, placebo; SGRQ, St George’s Respiratory Questionnaire (score); TDI, Transition Dyspnea 
Index; UMEC/VIL, umeclidinium–vilanterol fixed-dose combination.
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none of the comparative studies included in that analysis was 
double dummy or head to head.
Transition Dyspnea Index
For all the investigated LAMA/LABA combinations, sta-
tistically significant improvements in TDI were observed 
compared with monocomponents. However, the overall 
differences in TDI between LAMA/LABA FDC and mono-
therapies were small and did not exceed 0.5 units.22 Compared 
with monotherapies, differences between TIO/OLO and other 
LAMA/LABA FDCs were even smaller (0.3 units). The NNT 
to increase the TDI focal score by 1 unit was (compared 
with a LAMA) nine to 12 for TIO/OLO 5/5 µg,27,28 nine for 
GLY/IND,52 and 20 for UMEC/VIL 62.5/25 µg.53
Health-related quality of life
Overall, the investigated LAMA/LABA combinations 
reduced the SGRQ score significantly compared with mono-
components, with differences ranging between 1.3 and 1.5 
units compared with monotherapies for the different LAMA/
LABA FDCs. In this regard, differences between TIO/OLO 
and other LAMA/LABA FDCs did not exceed 0.2 units. 
Analysis of data reported in individual studies showed that the 
NNT to decrease the SGRQ score by 4 in patients already 
treated with TIO 5 µg ranged between nine and 12 for TIO/
OLO 5/5 (Table 3), between eleven and 16 for GLY/IND,54,55 
and 14 for UMEC/VIL.56 The ACL/FORM formulation did 
not significantly influence the ratio of responder patients.57
Hyperinflation and exercise
Network meta-analyses have thus far not addressed the 
effects of LAMA/LABA combinations on other clinically 
relevant outcomes, such as hyperinflation or exercise toler-
ance. The few available studies showed that reductions in 
FRC and RV measured 60 minutes after inhalation of GLY/
IND 62.5/25 µg were larger (520 and 520 mL, respectively) 
than those obtained with TIO 18 µg inhaled via HandiHaler 
(400 and 410 mL, respectively), leading to a recipro-
cal increase in IC of 150 mL with GLY/IND 62.5/25 µg 
compared with TIO 18 µg.50 These differences are in the 
same order of magnitude as the differences between TIO/
OLO 5/5 µg and TIO 5 µg. Reductions in hyperinflation, 
seen with GLY/IND 62.5/25 µg, were not translated into 
prolongations in endurance time on the cyclo-ergometer, 
which were similar to those obtained with TIO 18 µg via 
HandiHaler. The effects of inhaled UMEC/VIL 62.5/25 µg 
and UMEC 62.5 µg on endurance time during exercise 
were inconsistent:51 compared with placebo, endurance time 
increased by 69 (95% CI 24–114) and 22 (95% CI -14 to 58) 
seconds with UMEC/VIL 62.5/25 µg and by 25 (95% CI -41 
to 91) and 26.5 (95% CI -26 to 79) seconds with UMEC 
62.5 µg, respectively.
exacerbations
Research is ongoing to determine whether the TIO/OLO 5/5 
µg FDC is superior to TIO 5 µg in preventing COPD exac-
erbations. However, a few studies comparing other existing 
LAMA/LABA FDCs with a LAMA have already attempted 
to clarify the potential place of dual bronchodilatation in 
this regard. 
In one study, the effects of GLY/IND 50/110 µg, TIO 
18 µg (via HandiHaler), and GLY 50 µg on exacerbations 
were investigated during a 64-week trial in COPD patients 
who all belonged to stage III/IV (GOLD B and D, new 
classification).55 Interestingly, inclusion in that study was 
restricted to patients with a history of at least one COPD 
exacerbation requiring treatment with antibiotics and/or 
systemic corticosteroids within the previous year. GLY/IND 
50/110 µg significantly reduced the rate of all (mild, moder-
ate, and severe) exacerbations by 14% compared with TIO 
18 µg via HandiHaler and by 15% compared with GLY 50 
µg. The effect was largely driven by the reduction in mild 
exacerbations (about three per year), since the incidence of 
moderate and severe exacerbations was similar among the 
three groups.55 In that study, the NNT was 19 to prevent one 
exacerbation with GLY/IND 50/110 µg compared with TIO 
and 25 compared with GLY.55,58 
The FLAME study, a second 52-week-long study com-
paring the effects of GLY/IND 50/110 µg once daily with 
SALM/FLU 50/500 µg twice daily on the rate of COPD 
exacerbations, showed that dual bronchodilatation was 
more effective in reducing not only all (mild, moderate, and 
severe) exacerbations but also the number of both moderate 
and severe COPD exacerbations,53,59 with an NNT of 17 for 
moderate and severe exacerbations. Importantly, FLAME 
excluded all COPD patients with a history of asthma, con-
comitant allergic rhinitis, or very pronounced blood eosino-
philia (600 eosinophils/µL). 
Studies comparing the effects of UMEC/VIL and UMEC 
on exacerbations47,53,60,61 have not yielded conclusive results, 
possibly because of insufficient duration and less stringent 
patient selection.
Perspective: when to add a LABA to 
a LAMA in COPD?
The previous sections clearly demonstrate that TIO/OLO 
5/5 µg, formulated in the Respimat soft-mist inhaler, 
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substantially improves trough FEV
1
, TDI scores, markers 
of dynamic hyperinflation, and HR-QoL. Differences reach 
or even exceed the MCID for FEV
1
, TDI, and HR-QoL 
compared with placebo. TIO/OLO 5/5 µg also statistically 
improves spirometric variables, TDI scores, HR-QoL, and 
markers of hyperinflation compared to TIO 5 µg. However, 
the MCID between dual bronchodilatation and monotherapy 
is generally not reached.
Although efforts to grade and compare the effects of all 
available LAMA/LABA FDCs should be interpreted with cau-
tion, placebo-controlled studies and a network meta-analysis 
comparing the effects of TIO/OLO 5/5 µg with other available 
LAMA/LABA FDCs allow us to conclude that their overall 
effects on pulmonary function, HR-QoL, and TDI are com-
parable in magnitude. Therefore, if differences were to exist 
between different LABA/LAMA FDCs, these differences 
would be small and probably not clinically relevant. Pos-
sibly, the currently assessed end points and techniques used 
to investigate their effects are not sensitive enough to pick 
up the clinical impact of undeniable differences that prevail 
between available LAMA/LABA FDCs in terms of pharma-
cological characteristics of the individual LAMA and LABA 
components (eg, onset and duration of action, maximum effect 
and potency, receptor selectivity, lipophilicity, dissociation 
half-life, serum half-life, and metabolism issues).7,62,63 Only 
head-to-head comparisons can solve this issue.
The potential beneficial effects of dual bronchodilatation 
over monotherapies in the prevention of COPD exacerbations 
require further investigation, however. The limited data avail-
able on TIO/OLO 5/5 µg suggest that dual bronchodilatation 
was superior to OLO 5 µg but not to TIO 5 µg in preventing 
moderate-to-severe exacerbations, a finding that is in line 
with a recent network meta-analysis in which the effects 
of several LABA/LAMA combinations were reviewed.45 
Differences between TIO/OLO 5/5 µg and TIO 5 µg or 
OLO 5 µg do not appear to exist for severe exacerbations,27 
and Oba et al came to the same conclusions for all LABAs, 
LAMAs, and LAMA/LABA FDCs.45 The apparently intrigu-
ing observation that long-acting bronchodilators prevent 
better against mild and moderate exacerbations than against 
severe exacerbations may be attributed to several factors. 
First, the specific actions of long-acting bronchodilators 
might not affect the frequency of exacerbations per se, but 
through reducing breathlessness may increase the threshold 
at which a given patient will consider his/her worsening 
sufficiently severe to be labeled an exacerbation.64 Secondly, 
LAMA-containing combinations could further enhance that 
protective effect in reducing mucus hypersecretion, although 
hard evidence is still lacking to support this contention. 
Thirdly, the efficacy of active treatments in preventing severe 
exacerbations (requiring hospitalization) is difficult to prove 
in classical RCTs, where COPD patients are closely moni-
tored (encompassing regular study visits and daily monitoring 
of symptoms and spirometry). Due to this intensive proactive 
monitoring in classical RCTs, COPD patients experiencing 
increased symptoms of an ensuing exacerbation are treated 
promptly (with an increase in inhaled bronchodilators, oral 
corticosteroids, and/or antibiotics), preventing further clinical 
deterioration and thereby the need for hospital admissions. 
Therefore, and due to exclusion of COPD patients with sig-
nificant comorbidities, the incidence of hospitalizations due 
to COPD exacerbations are rare events in classical RCTs.
In the past, it was deemed unlikely that bronchodilat-
ing drugs would affect the acute inflammatory response 
to respiratory infections or exposure to airway irritants 
accompanying more severe exacerbations, which give 
rise to symptoms that eventually require treatment with 
anti-inflammatory drugs.64 This hypothesis has however been 
recently challenged by the FLAME study, which concluded 
that GLY/IND 50/110 µg once daily provided better protec-
tion than a SALM/FLU 50/500 µg FDC twice daily against 
mild, moderate, and severe exacerbations in COPD GOLD 
stage B and D patients.47,53,60,61 It is crucially important to note 
that all COPD patients who might potentially have experi-
enced beneficial effects from an ICS treatment (previous 
asthma, asthma COPD overlap syndrome, increased blood 
eosinophilia, and allergic rhinitis) were completely excluded 
from that study, maximizing in this way the effect of dual 
bronchodilatation. Unfortunately, this study did not address 
the issue of whether dual bronchodilatation is superior to a 
LAMA in preventing severe exacerbations in that subgroup 
of COPD patients.59
TIO/OLO 5/5 µg reduced markers of hyperinflation, 
such as FRC, compared to monotherapies, the difference 
exceeding 200 mL 22 hours after inhalation. The exact 
meaning of a 200 mL reduction in FRC is unknown, since its 
MCID has not been determined so far. At that time point, the 
effects of the monotherapies on FRC (Figure 1) have almost 
completely disappeared.27,51 Despite its substantial effects 
on dynamic hyperinflation, dual bronchodilatation does 
not increase endurance time during constant work exercise 
compared to monotherapies, a feature that TIO/OLO 5/5 µg 
shares with other LAMA/LABA FDCs.31,32,50,51 The reasons 
for the additional improvement in markers of hyperinflation 
seen with dual bronchodilatation are not translated into addi-
tional gains in endurance time are unclear. Patient selection 
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may definitely play a role, since TIO/OLO 5/5 µg enhances 
endurance time during constant work exercise in severely 
hyperinflated patients31 compared to monotherapies. Another 
possibility is that a ventilatory-limited COPD patient may 
become limited by peripheral muscle weakness once treated 
with one bronchodilator. In such a case, the addition of a sec-
ond long-acting bronchodilator will not affect exercise endur-
ance, unless the prevailing limiting factor, the peripheral 
muscle weakness, is treated. Studies comparing the effects of 
dual bronchodilatation with monotherapy on the outcome of a 
pulmonary rehabilitation program could answer this question. 
Interestingly, the impact of optimization of bronchodilatation 
on the outcome of pulmonary rehabilitation has been nicely 
demonstrated previously with TIO monotherapy.18
American, European, and Japanese regulatory authori-
ties have licensed a number of LAMA/LABA FDCs to treat 
COPD patients for symptom relief and pulmonary function 
improvement. Currently, the question remains unanswered 
as to whether all patients with COPD or only some pheno-
types within the COPD-patient group should be treated with 
a LAMA/LABA FDC. Indeed, the current GOLD guidelines 
recommend maintenance therapy with either a LAMA or 
LABA in symptomatic patients with moderate or severe 
COPD. When patients are not adequately controlled with a 
single long-acting bronchodilator, combining a LAMA with 
a LABA may be beneficial. An ICS/LABA combination is an 
option for maintenance treatment in COPD patients who are at 
high risk of exacerbations,1 especially if these exacerbations 
require treatment with oral corticosteroid courses only (without 
antibiotics). However, ICS/LABA combinations are often pre-
scribed to patients who do not qualify for this criterion.65,66
It is tempting to initiate a treatment with a LABA/
LAMA FDC in every new symptomatic COPD patient, since 
dual bronchodilatation yields superior effects compared to 
monotherapies and will result in MCIDs in the domains of 
pulmonary function, dyspnea, and HR-QoL compared with 
placebo. However, a substantial number of patients do well 
with monotherapy, such that this surplus in bronchodilata-
tion does not always lead to better QoL, improved endurance 
time, or fewer exacerbations in every single patient.45 Indeed, 
differences between dual bronchodilatation and monotherapy 
generally remain below the currently accepted MCIDs for 
a number of domains. It has thus been suggested that the 
current thresholds used to define an MCID when comparing 
two active treatments be redefined.38
Another option is to perform a responder analysis in 
studies assessing the effects of long-acting bronchodilators. 
This demonstrates that certain patients already reach the 
MCID with one bronchodilator, and that this proportion 
may be increased by selective prescription of dual bron-
chodilatation in patients not responding to monotherapy.38 
The proposed strategy combines a personalized approach 
of the patient with an optimal use of health care resources, 
and should remain the strategy of choice, at least as long as 
price differences between dual bronchodilatation and mono-
therapies remain substantial. Moreover, this is in line with 
a general rule in medicine, which says not to treat patients 
with two medicines if satisfactory results may be obtained 
with only one medicine. Nevertheless, responder analyses 
and NNT calculations reported in clinical trials with COPD 
should be approached with caution, since a Hawthorne effect 
appears to be present in many trials, minimizing the effect of 
the intervention.38 Therefore, the currently available efficacy 
data from classical RCTs should be completed with effective-
ness data obtained in real-life studies (ie, pragmatic trials and 
observational studies), which may yield more realistic data in 
this regard. Importantly, whereas the aforementioned classical 
RCTs had high internal validity thanks to randomization and 
double-blind design, their external validity might be limited 
due to a (highly) selected COPD patient population that is not 
representative of the full spectrum of COPD patients seen in 
clinical practice. This has implications for real-life effective-
ness (and comparative effectiveness), as well as long-term 
safety in a real-world setting, since many patients COPD with 
comorbidities (asthma, cardiovascular disease, heart failure) 
and polypharmacy are excluded from classical RCTs.67
If the evidence is currently lacking to initiate dual bron-
chodilatation in every COPD patient at the time of diagnosis, 
clinical studies suggest that the threshold to prescribe dual 
bronchodilatation should be low in patients who remain 
symptomatic under monotherapy, in highly breathless or 
hyperinflated COPD patients, in those included in a pulmo-
nary rehabilitation program, and in those patients in COPD 
GOLD subgroups B and D who comply with the stringent 
inclusion and exclusion criteria of the recently published 
FLAME study.
To support early treatment of COPD patients with dual 
bronchodilatation, additional studies should be conducted 
to demonstrate its disease-modifying effect. The protocol 
that should be followed to conduct such an early interven-
tion study was proposed some years ago.68 Interestingly, 
a prespecified analysis of the UPLIFT trial showed that TIO 
significantly reduced the rate of decline of postbronchodilator 
FEV
1
 relative to control in patients with COPD stage II, a 
feature that was not present in more severe COPD stages.69
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Conclusion
In conclusion, TIO/OLO 5/5 µg is a LAMA/LABA FDC 
formulated in a Respimat soft-mist inhaler that has been 
thoroughly investigated in over 10,000 COPD patients. Its 
effects on a variety of relevant clinical end points, including 
lung function, symptoms (TDI), and QoL (SGRQ), are com-
parable to other LAMA/LABA FDCs. In a COPD popula-
tion at relatively low risk of exacerbations, TIO/OL 5/5 µg 
significantly reduced the rate of exacerbations compared 
with OLO 5 µg monotherapy, but not compared to TIO 5 µg 
monotherapy. Larger long-term studies in COPD patients at 
high risk of exacerbations are required and ongoing to inves-
tigate whether TIO/OLO 5/5 µg is also superior to TIO 5 µg 
monotherapy in reducing moderate and severe COPD exac-
erbations. Clinical studies with TIO/OLO 5/5 µg and other 
LAMA/LABA FDCs support their use in COPD patients who 
remain symptomatic and patients who frequently exacerbate 
and exhibit some well-defined COPD phenotypes.
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